Monoclonal antibodies in the study and therapy of hematopoietic cancers.
Recent advances utilizing monoclonal antibodies to phenotype acute leukemias have revealed no prognostic significance of the expression of lymphoid-associated antigens by acute myeloid leukemia blasts and conflicting results regarding 'biphenotypic' acute myeloid leukemia. Several studies treating patients with refractory lymphoma with immunotoxins reported encouraging results but significant production of anti-mouse or anti-toxin antibody. Radiolabeled antibodies that react with panhematopoietic antigens have delivered selective radiation to marrow, spleen and lymph nodes in animal models and are being used in Phase I studies of marrow transplantation for acute leukemia.
Matthews
D C
DC
Fred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington, Seattle 98104.
Smith
F O
FO
Bernstein
I D
ID
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D011379:Prognosis; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000922:Immunotoxins